EC Approves Alectinib for ALK+ NSCLC

February 24th, 2017 – The European Commission has approved alectinib as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) following progression on crizotinib, according to Roche, the developer of the second-generation ALK inhibitor. The approval, which follows a positive opinion from the Committee for Medicinal Products for Human Use, is based on data from 2 phase II trials. In the first study, labeled NP28761, the … (leggi tutto)